leadf
logo-loader
viewMarrone Bio Innovations
(
NASDAQ:MBII
)

Marrone Bio 3Q revenue grows as seed sales take root

In the US, Marrone’s biological seed treatments for corn and soybeans are entering their third year on the market and delivered a sales increase in the three months ended September 30

Sprouts growing from stacks of quarters leading to a jar of quarters
Marrone Bio posted an adjusted net loss that narrowed 63% year-over-year to $6.1 million

Marrone Bio Innovations Inc (NASDAQ:MBII) reported third-quarter revenue Monday that grew 27% year-over-year to $8.8 million thanks in part to the company’s strategic expansion in international and seed treatment markets.

In the US, Marrone’s biological seed treatments for corn and soybeans are entering their third year on the market and delivered a sales increase in the three months ended September 30. Elsewhere, sales also benefited from the introduction in Latin America of a new foliar treatment to promote plant health for soybeans.

That helped lead to an adjusted net loss that narrowed 63% to $6.1 million from $16.4 million in the same period a year earlier. Gross profit, meanwhile, increased 40% to $5 million from $3.6 million.

READ: Marrone Bio adds former Lowe's executive Lara Lee to its board

“Our third-quarter results were particularly encouraging as we delivered on our ambitions to expand our international presence and to further penetrate the seed treatment market for row crops,” CEO Kevin Helash said in a statement. “The benefit of this strategic shift was reflected in another quarter of gross margins in line with our annual target in the mid-50% range, and sales that keep us on track to achieve full-year revenue growth in the range of our historical levels.”

Heash noted that the second half of the year normally means lower revenue, but that the company remains on pace to maintain its growth. 

“While we are expanding our business in Latin America, the second half of the year is typically a smaller period for us in terms of revenue,” Helash added. “While we anticipate that our 2020 full-year revenues will be in the range of our historical growth rate, we continue to believe that our sales mix will continue on the historical trend of being stronger in the first half of the year than the second, and will continue to do so as we move forward.”

On a nine-month basis, revenue increased 35% from 2019 to 2020 ( $30.7 million compared to $22.7 million). The company’s adjusted net loss was $16 million, a 41% increase from $27 million. 

Based in Davis, California, Marrone Bio holds more than 400 issued and pending patents and has brought six US Environmental Protection Agency-registered biological product lines and one biostimulant to market. 

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Marrone Bio Innovations

Follow
NASDAQ:MBII

Price: 0.8199 USD

Market Cap: $144.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Proactive Presents a Livestream Event with Nextech AR Solutions

Proactive's Steve Darling presents a Livestream Chat with NextTech AR Solutions Joining the chat Evan Gappelberg - CEO and Founder Paul Duffy - President and Chairman of the Board Mirjana Prpa - AR Product Manager and Head of AI Division Baran Korkmaz - Founder of ARway

1 hour, 15 minutes ago

2 min read